Previous Close | 2.2600 |
Open | 2.2900 |
Bid | 2.2000 x 600 |
Ask | 2.2600 x 700 |
Day's Range | 2.2200 - 2.2900 |
52 Week Range | 1.0800 - 3.7900 |
Volume | |
Avg. Volume | 3,115,650 |
Market Cap | 145.333M |
Beta (5Y Monthly) | 1.55 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.5800 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.20 |
Financial and Clinical Progress Amidst Net Loss Wider Than Estimates
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.